On Sept. 4, the U.S. Food and Drug Administration (FDA) approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria, a rare metabolic disorder that has been reported in about 20 patients worldwide.
Most Recent Content
For Nurse Practitioners
Do Vitamins, Plants Help Uterine Fibroid Risk or Treatment?
A research team out of Poland recently undertook a comprehensive examination of published data to determine the role that vitamins and diet might play...
